Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Total Liabilities: 2019-2024

Historic Total Liabilities for Fulcrum Therapeutics (FULC) over the last 6 years, with Dec 2024 value amounting to $17.7 million.

  • Fulcrum Therapeutics' Total Liabilities fell 24.06% to $16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.5 million, marking a year-over-year decrease of 24.06%. This contributed to the annual value of $17.7 million for FY2024, which is 21.41% down from last year.
  • As of FY2024, Fulcrum Therapeutics' Total Liabilities stood at $17.7 million, which was down 21.41% from $22.5 million recorded in FY2023.
  • Over the past 5 years, Fulcrum Therapeutics' Total Liabilities peaked at $34.4 million during FY2020, and registered a low of $17.7 million during FY2024.
  • Its 3-year average for Total Liabilities is $22.6 million, with a median of $22.5 million in 2023.
  • As far as peak fluctuations go, Fulcrum Therapeutics' Total Liabilities spiked by 47.71% in 2020, and later crashed by 31.79% in 2021.
  • Over the past 5 years, Fulcrum Therapeutics' Total Liabilities (Yearly) stood at $34.4 million in 2020, then tumbled by 31.79% to $23.5 million in 2021, then climbed by 18.25% to $27.7 million in 2022, then declined by 18.89% to $22.5 million in 2023, then decreased by 21.41% to $17.7 million in 2024.